Your browser is no longer supported. Please, upgrade your browser.
Caladrius Biosciences, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own1.70% Shs Outstand19.41M Perf Week-13.90%
Market Cap120.38M Forward P/E- EPS next Y-0.41 Insider Trans5.50% Shs Float15.99M Perf Month-5.88%
Income-7.70M PEG- EPS next Q-0.08 Inst Own7.20% Short Float9.08% Perf Quarter32.41%
Sales- P/S- EPS this Y56.90% Inst Trans11.70% Short Ratio0.27 Perf Half Y0.52%
Book/sh1.67 P/B1.15 EPS next Y40.70% ROA- Target Price- Perf Year-25.29%
Cash/sh0.55 P/C3.48 EPS next 5Y- ROE- 52W Range1.05 - 4.89 Perf YTD34.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.74% Beta1.22
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low82.86% ATR0.34
Employees27 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)45.83 Volatility15.09% 12.65%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close1.92
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume5.42M Price1.92
Recom2.30 SMA20-12.65% SMA50-0.00% SMA2001.68% Volume0 Change0.00%
May-18-20Downgrade Dawson James Buy → Neutral
Nov-20-18Resumed H.C. Wainwright Buy $18.50
Aug-23-16Initiated Chardan Capital Markets Buy $6.50
Apr-29-16Upgrade H.C. Wainwright Neutral → Buy $1.25
Jan-08-16Downgrade H.C. Wainwright Buy → Neutral
Jan-07-16Downgrade Maxim Group Buy → Hold
Dec-22-15Reiterated Maxim Group Buy $12 → $4
Feb-25-21 04:05PM  
Feb-18-21 04:05PM  
Feb-17-21 01:59PM  
Feb-12-21 08:15AM  
Jan-25-21 05:05PM  
Jan-21-21 09:00AM  
Jan-20-21 02:25PM  
Jan-19-21 08:00AM  
Jan-06-21 08:30AM  
Dec-14-20 08:29AM  
Dec-10-20 08:30AM  
Dec-09-20 04:05PM  
Nov-29-20 08:15PM  
Nov-17-20 04:05PM  
Nov-10-20 08:30AM  
Nov-05-20 04:05PM  
Nov-04-20 08:30AM  
Nov-02-20 08:30AM  
Oct-29-20 08:30AM  
Oct-21-20 08:30AM  
Oct-17-20 09:14AM  
Oct-08-20 08:00AM  
Oct-07-20 04:05PM  
Oct-06-20 04:05PM  
Sep-21-20 08:35AM  
Sep-14-20 08:35AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-03-20 08:00AM  
Sep-01-20 04:34PM  
Aug-27-20 08:00AM  
Aug-13-20 04:05PM  
Aug-06-20 08:30AM  
Aug-05-20 04:05PM  
Jul-28-20 08:00AM  
Jun-02-20 08:06AM  
May-28-20 01:20PM  
May-26-20 08:00AM  
May-14-20 03:42PM  
May-13-20 12:16AM  
May-12-20 11:15AM  
May-07-20 04:05PM  
May-06-20 08:30AM  
Apr-30-20 08:30AM  
Apr-27-20 03:16PM  
Apr-23-20 02:00PM  
Apr-22-20 08:00AM  
Apr-20-20 07:14AM  
Mar-26-20 10:17AM  
Mar-17-20 07:00AM  
Mar-06-20 09:22AM  
Mar-05-20 04:05PM  
Feb-27-20 08:30AM  
Feb-03-20 08:30AM  
Jan-27-20 09:17AM  
Jan-21-20 07:35AM  
Jan-07-20 04:05PM  
Dec-02-19 04:05PM  
Nov-25-19 08:56AM  
Nov-19-19 05:56PM  
Nov-16-19 03:59PM  
Nov-06-19 04:05PM  
Nov-04-19 08:44AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Oct-23-19 11:30AM  
Oct-14-19 11:58AM  
Oct-01-19 08:30AM  
Sep-24-19 09:04AM  
Sep-06-19 10:15AM  
Sep-05-19 04:05PM  
Sep-04-19 08:58AM  
Aug-15-19 09:57AM  
Aug-08-19 04:05PM  
Aug-07-19 08:30AM  
Aug-05-19 10:55AM  
Aug-01-19 08:30AM  
Jul-25-19 03:04PM  
Jul-15-19 08:30AM  
Jun-04-19 08:30AM  
May-24-19 03:53AM  
May-09-19 04:05PM  
May-07-19 08:30AM  
May-02-19 08:30AM  
Apr-25-19 02:23PM  
Apr-03-19 08:30AM  
Mar-14-19 04:23PM  
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidson Michael H.DirectorSep 09Buy1.8055,52599,945106,588Sep 10 04:01 PM